New Delhi: Indian vaccine maker Bharat Biotech on Thursday said its vaccine against COVID-19 was now a universal vaccine for adults and children. “Covaxin is now a universal vaccine for adults and children. Our goals of developing a global vaccine against COVID-19 have been achieved and all product development for licensure has been completed,” the Hyderabad-based pharmaceutical firm said.
Earlier, Bharat Biotech had claimed that the booster dose of Covaxin can neutralise both Delta and Omicron variants of coronavirus. “Results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of Covaxin (BBV152) six months after getting a primary two-dose series of Covaxin, neutralised the SARS-CoV-2 Omicron and Delta variants,” the company had said in a statement.
It also mentioned that earlier studies demonstrated the neutralising potential of Covaxin against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Omicron, Zeta and Kappa.
Citing the study results, Bharat Biotech noted that more than 90 per cent of all individuals boosted with Covaxin showed neutralising antibodies.
“As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern. Data from this preliminary analysis show individuals receiving a booster dose of Covaxin have a significant immune response to both the Omicron and Delta variants.
“These findings suggest that a booster dose has the potential to reduce disease severity and hospitalisations,” Emory Vaccine Center Assistant Professor Mehul Suthar, who led the laboratory analysis, noted.
Bharat Biotech Chairman and Managing Director Krishna Ella said the vaccine major is in a continuous state of innovation and product development for Covaxin.
“The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine generating both humoral and cell mediated immune responses.
(With PTI inputs)